ReproNovo Phase 2 fertility study doses first participant

ReproNovo has dosed the first participant in its phase 2 NORDIC study evaluating RPN-002, an investigational therapy designed to improve embryo implantation during assisted reproductive technology (ART). The randomised, double-blind, placebo-controlled trial will enrol 120 participants across five European sites and will investigate whether higher doses and longer treatment schedules can reduce uterine contractions around […] The post ReproNovo Phase 2 fertility study doses first participant appeared first on Pharmafile.

Continue reading →